ARWR
Price
$19.76
Change
-$0.30 (-1.50%)
Updated
Nov 5, 10:48 AM (EDT)
20 days until earnings call
UCBJY
Price
$97.31
Change
-$0.00 (-0.00%)
Updated
Nov 4 closing price
114 days until earnings call
Ad is loading...

ARWR vs UCBJY

Header iconARWR vs UCBJY Comparison
Open Charts ARWR vs UCBJYBanner chart's image
Arrowhead Pharmaceuticals
Price$19.76
Change-$0.30 (-1.50%)
Volume$900
CapitalizationN/A
UCB S.A
Price$97.31
Change-$0.00 (-0.00%)
Volume$129.97K
CapitalizationN/A
View a ticker or compare two or three
ARWR vs UCBJY Comparison Chart
Loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
UCBJY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
ARWR vs. UCBJY commentary
Nov 05, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ARWR is a StrongSell and UCBJY is a Buy.

COMPARISON
Comparison
Nov 05, 2024
Stock price -- (ARWR: $20.06 vs. UCBJY: $97.31)
Brand notoriety: ARWR: Notable vs. UCBJY: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ARWR: 58% vs. UCBJY: 610%
Market capitalization -- ARWR: $2.49B vs. UCBJY: $37.22B
ARWR [@Biotechnology] is valued at $2.49B. UCBJY’s [@Biotechnology] market capitalization is $37.22B. The market cap for tickers in the [@Biotechnology] industry ranges from $498.83B to $0. The average market capitalization across the [@Biotechnology] industry is $2.82B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ARWR’s FA Score shows that 1 FA rating(s) are green whileUCBJY’s FA Score has 3 green FA rating(s).

  • ARWR’s FA Score: 1 green, 4 red.
  • UCBJY’s FA Score: 3 green, 2 red.
According to our system of comparison, UCBJY is a better buy in the long-term than ARWR.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ARWR’s TA Score shows that 4 TA indicator(s) are bullish while UCBJY’s TA Score has 4 bullish TA indicator(s).

  • ARWR’s TA Score: 4 bullish, 4 bearish.
  • UCBJY’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, UCBJY is a better buy in the short-term than ARWR.

Price Growth

ARWR (@Biotechnology) experienced а -0.59% price change this week, while UCBJY (@Biotechnology) price change was +1.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.74%. For the same industry, the average monthly price growth was +10.27%, and the average quarterly price growth was +7.68%.

Reported Earning Dates

ARWR is expected to report earnings on Feb 05, 2025.

UCBJY is expected to report earnings on Feb 27, 2025.

Industries' Descriptions

@Biotechnology (-1.74% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
UCBJY($37.2B) has a higher market cap than ARWR($2.49B). UCBJY YTD gains are higher at: 125.618 vs. ARWR (-34.444). UCBJY has higher annual earnings (EBITDA): 1.12B vs. ARWR (-508.26M). UCBJY has more cash in the bank: 689M vs. ARWR (434M). ARWR has less debt than UCBJY: ARWR (118M) vs UCBJY (3.04B). UCBJY has higher revenues than ARWR: UCBJY (5.45B) vs ARWR (19.6M).
ARWRUCBJYARWR / UCBJY
Capitalization2.49B37.2B7%
EBITDA-508.26M1.12B-45%
Gain YTD-34.444125.618-27%
P/E RatioN/A146.71-
Revenue19.6M5.45B0%
Total Cash434M689M63%
Total Debt118M3.04B4%
FUNDAMENTALS RATINGS
ARWR vs UCBJY: Fundamental Ratings
ARWR
UCBJY
OUTLOOK RATING
1..100
578
VALUATION
overvalued / fair valued / undervalued
1..100
95
Overvalued
2
Undervalued
PROFIT vs RISK RATING
1..100
10013
SMR RATING
1..100
9894
PRICE GROWTH RATING
1..100
6436
P/E GROWTH RATING
1..100
28
SEASONALITY SCORE
1..100
65n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

UCBJY's Valuation (2) in the null industry is significantly better than the same rating for ARWR (95) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.

UCBJY's Profit vs Risk Rating (13) in the null industry is significantly better than the same rating for ARWR (100) in the Biotechnology industry. This means that UCBJY’s stock grew significantly faster than ARWR’s over the last 12 months.

UCBJY's SMR Rating (94) in the null industry is in the same range as ARWR (98) in the Biotechnology industry. This means that UCBJY’s stock grew similarly to ARWR’s over the last 12 months.

UCBJY's Price Growth Rating (36) in the null industry is in the same range as ARWR (64) in the Biotechnology industry. This means that UCBJY’s stock grew similarly to ARWR’s over the last 12 months.

ARWR's P/E Growth Rating (2) in the Biotechnology industry is in the same range as UCBJY (8) in the null industry. This means that ARWR’s stock grew similarly to UCBJY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ARWRUCBJY
RSI
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
71%
Bearish Trend 1 day ago
38%
Momentum
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
61%
MACD
ODDS (%)
Bullish Trend 1 day ago
74%
Bullish Trend 1 day ago
74%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bullish Trend 1 day ago
66%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 1 day ago
73%
Advances
ODDS (%)
Bullish Trend 1 day ago
78%
Bullish Trend 7 days ago
64%
Declines
ODDS (%)
Bearish Trend 6 days ago
83%
Bearish Trend 21 days ago
54%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
33%
Aroon
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
72%
View a ticker or compare two or three
Ad is loading...
ARWR
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
UCBJY
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MLPAX7.980.07
+0.88%
Invesco SteelPath MLP Alpha A
TRASX16.030.03
+0.19%
T. Rowe Price Asia Opportunities I
AASMX23.840.04
+0.17%
Thrivent Small Cap Stock A
MEIHX52.83-0.14
-0.26%
MFS Value R3
ARTLX15.39-0.06
-0.39%
Artisan Value Investor

ARWR and

Correlation & Price change

A.I.dvisor indicates that over the last year, ARWR has been loosely correlated with NTLA. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if ARWR jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ARWR
1D Price
Change %
ARWR100%
+2.92%
NTLA - ARWR
51%
Loosely correlated
+2.30%
EDIT - ARWR
49%
Loosely correlated
-1.03%
BEAM - ARWR
48%
Loosely correlated
+6.24%
ALNY - ARWR
46%
Loosely correlated
-1.45%
AXON - ARWR
46%
Loosely correlated
+1.35%
More

UCBJY and

Correlation & Price change

A.I.dvisor tells us that UCBJY and GBIO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that UCBJY and GBIO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To UCBJY
1D Price
Change %
UCBJY100%
-0.74%
GBIO - UCBJY
28%
Poorly correlated
-1.81%
VANI - UCBJY
26%
Poorly correlated
-2.33%
ABOS - UCBJY
24%
Poorly correlated
+3.69%
TNYA - UCBJY
23%
Poorly correlated
+24.70%
ARWR - UCBJY
23%
Poorly correlated
+2.92%
More